← All trials
NCT04171739
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2019
- Primary completion
- Feb 11, 2020
- Completion date
- Feb 11, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- F2G Ltd.Lead sponsor
- Hammersmith Medicines ResearchCollaborator
- Hammersmith Medicines ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.